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Abstract
Background: Incontinence has a greater detrimental effect on quality of life than other
symptoms of overactive bladder (OAB) and is often difficult to treat with antimuscarinic
monotherapy.
Objective: To evaluate the efﬁcacy and the safety and tolerability of combination
(solifenacin 5 mg and mirabegron 50 mg) versus solifenacin 5 or 10 mg in OAB patients
remaining incontinent after 4 wk of solifenacin 5 mg.
Design, setting, and participants: OAB patients remaining incontinent despite daily
solifenacin 5 mg during 4-wk single-blind run-in were randomised 1:1:1 to double-
blind daily combination or solifenacin 5 or 10 mg for 12 wk. Patients receiving the
combination were initiated on mirabegron 25 mg increasing to 50 mg after week 4.
Outcome measurements and statistical analysis: The primary end point was a change
from baseline to end of treatment (EOT) in the mean number of incontinence episodes
per 24 h (stratiﬁed rank analysis of covariance [ANCOVA]). Key secondary end points
were a change from baseline to EOT in the mean number of micturitions per 24 h
(ANCOVA) and number of incontinence episodes noted in a 3-d diary at EOT (mixed-
effects Poisson regression). A trial [12_TD$DIFF] (BESIDE) comparing combination treatment
(solifenacin plus mirabegron) with one treatment alone (solifenacin[1_TD$DIFF]) tested the superi-
ority of combination versus solifenacin 5 mg, noninferiority (and potential superiority)
of combination versus solifenacin 10 mg (key secondary end points), and the safety and
tolerability of combination therapy versus solifenacin monotherapy.
Results and limitations: A total of 2174 patients were randomised to combination
(n = 727), solifenacin 5 mg (n = 728), or solifenacin 10 mg (n = 719). At EOT, combination
was superior to solifena
ictu(p = 0.001), daily m* Corresponding author. Un
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(p = 0.014). Combination was noninferior to solifenacin 10 mg for key secondary end points
and superior to solifenacin 10 mg for improving dailymicturitions. All treatmentswerewell
tolerated.
Conclusions: Adding mirabegron 50 mg to solifenacin 5 mg further improved OAB symp-
toms versus solifenacin 5 or 10 mg, and it was well tolerated in OAB patients remaining
incontinent after initial solifenacin 5 mg.
Patient summary: In this 12-wk study, overactive bladder patients who remained inconti-
nent despite initial solifenacin 5 mg treatment received additional treatment with mir-
abegron 50 mg. Combining mirabegron 50 mg with solifenacin 5 mg was superior to
solifenacin 5 mg alone in improving symptoms of incontinence and frequent urination,
and it was well tolerated.
Trial registration: ClinicalTrials.gov NCT01908829.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Overactive bladder (OAB) syndrome is a symptom complex
defined as urinary urgency, usually accompanied by
increased daytime frequency and nocturia, with or without
urgency incontinence, in the absence of urinary tract
infection or other obvious pathology [1,2]. Urgency incon-
tinence is present in approximately one-third of OAB cases
[3]. Comparedwith other OAB symptoms, it has the greatest
impact on quality of life (QoL), with higher rates reported
for depression, psychological and emotional distress, and
social isolation [4]. Incontinence is associated with signifi-
cantly higher health care resource utilisation and lower
productivity [5]; consequently, incontinence has a major
socioeconomic impact.
Oral pharmacotherapies consist of antimuscarinics (eg,
solifenacin) and mirabegron, the b3-adrenoceptor agonist.
Both classes of drugs share similar efficacy, but mirabegron
is not associated with anticholinergic adverse events (AEs;
eg, the incidence of dry mouth is comparable with placebo)
[6]. In current clinical practice, patients are often initiated
on antimuscarinics; however, symptom improvement is
often insufficient [7], leading to dissatisfaction, particularly
if incontinence persists. Increasing the antimuscarinic dose
often exacerbates anticholinergic AEs that can lead to
treatment discontinuation [7,8]. If oral therapy fails,
intravesical onabotulinumtoxinA can be used to treat
OAB symptoms [9,10], but it is associated with urinary
tract infections, fluctuating response, and may require
intermittent self-catheterisation [11]. Other invasive alter-
natives include percutaneous tibial nerve stimulation and
sacral nerve stimulation [12,13], but their penetrance in
clinical practice is limited.
A trial [13_TD$DIFF] (BESIDE, NCT01908829) comparing combination
treatment (solifenacin plus mirabegron) with one treat-
ment alone (solifenacin[2_TD$DIFF]) tested the superiority of a 12-wk
combination (solifenacin 5 mg and mirabegron 25 mg
increasing to 50 mg after week 4) versus solifenacin 5 mg
in OAB patients remaining incontinent after 4 wk of
solifenacin 5 mg. The primary objective was to evaluate
the efficacy of combination versus solifenacin 5 mg. Second-
ary objectives were to evaluate the safety/tolerability of
combination versus solifenacin 5 or 10 mg, and the
noninferiority of combination versus solifenacin 10mg.
Initial experiencewith the combination, based on the resultsfrom an open-label postmarketing Japanese study, suggest
good efficacy and tolerability with add-on mirabegron 25 or
50 mg to solifenacin 2.5 or 5 mg compared with solifenacin
monotherapy [14].
2. Patients and methods
2.1. Study design and participants
In this randomised double-blind parallel-group multicentre phase 3B
study, patients aged18 yr with OAB symptoms for3mo, including an
average of two or more incontinence episodes per 24 h, entered a 2-wk
screening/washout period (visit 1) to remove the effects of previous OAB
medication and familiarise themselves with the electronic micturition
diary. After 4 wk of single-blind daily solifenacin 5 mg, patients
remaining incontinent at baseline (one or more episodes during the
3-d diary), were eligible for double-blind treatment (Fig. 1).
Patients who satisﬁed inclusion and did not meet exclusion criteria
(Supplementary Table 1) were randomised 1:1:1 to 12 wk of daily
double-blind treatment with combination (solifenacin 5 mg and
mirabegron 25 mg increasing to 50 mg after week 4), solifenacin
5 mg, or solifenacin 10 mg (Supplement 1).
2.2. Efficacy and safety assessments
During the double-blind period, efﬁcacy was assessed using a 3-d diary
prior to each study visit. The primary efﬁcacy end point was change from
baseline to end of treatment (EOT) in mean number of incontinence
episodes per 24 h. Key secondary efﬁcacy end points were change from
baseline to EOT inmean number ofmicturitions per 24 h and the number
of incontinence episodes noted in the 3-d diary at EOT. In the full analysis
set (FAS; randomised patients who received one or more doses of
double-blind treatment, one or more micturitions at baseline and after
baseline, and one or more incontinence episodes at baseline), the
primary comparison was combination versus solifenacin 5 mg; combi-
nation versus solifenacin 10 mg was a secondary analysis. A noninfer-
iority comparison between combination and solifenacin 10 mg was
performed for the key secondary end points in the per protocol set (PPS;
FAS patients without major protocol violations). If noninferiority was
demonstrated, the superiority of combination versus solifenacin 10 mg
would be investigated.
Other secondary end points included change from baseline to weeks
4, 8, 12, and EOT in the mean number of urgency episodes (grade 3/4 on
the Patient Perception of Intensity of Urgency Scale per 24 h [15]) mean
volume voided micturition, mean number of urgency incontinence
episodes per 24 h, mean number of pads per 24 h, mean number
of nocturia episodes, Patient Perception of Bladder Condition score
[16], and the percentage of patients (‘‘responders’’) achieving zero
[(Fig._1)TD$FIG]
Fig. 1 – Study design.
QD = every day.
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were also assessed at weeks 4, 8, and 12.
Safety assessments in the safety analysis set (randomised patients
who received one or more doses of double-blind treatment) at each
study visit and during the 2-wk single-blind placebo follow-up included
the frequency of treatment-emergent AEs (TEAEs) and TEAEs of special
interest (eg, antimuscarinic related), change from baseline in vital signs
(systolic blood pressure [SBP], diastolic blood pressure, and pulse rate),
12-lead electrocardiogram (ECG), and postvoid residual (PVR) volume
(assessed by bladder scan). Laboratory assessments were collected at
screening, baseline, and EOT.
2.3. Statistical analysis
Sample size was based on previous studies with mirabegron alone and in
combination with solifenacin [17–20]. A total of 610 patients per group
provided 80% power to analyse incontinence based on a (nonparametric)
Wilcoxon rank sum test based on ordered categories derived from the
previous studies, and provided 90%power to detect a 20% reduction in 3-d
incontinence episodes; 614 patients per group provided 90% power to
detect a 0.50 reduction in daily micturitions for combination versus
solifenacin 5 mg. Assuming a 15% dropout rate during the double-blind
period, 724 patientswere to be randomised to each group (Supplement2).
Demographic and baseline OAB characteristics and all efﬁcacy
analyses were described in the FAS, except noninferiority comparisons,
whichwere analysed in the PPS, in accordance with regulatory guidance.
Last observation carried forwardwas used for patients who discontinued
before week 12.
The primary end point (change from baseline to EOT in daily
incontinence episodes) was analysed using a separate stratiﬁed rank
analysis of covariance (ANCOVA) model to calculate the p value for thecomparison of combination versus solifenacin 5 mg. An ANCOVA model
with treatment group and randomisation stratiﬁcation factors including
sex, age (<65, 65 yr), and 4-wk incontinence episode reduction group
(<50%,50%) as ﬁxed factors, andmean daily incontinence at baseline as
the covariate was used to calculate adjusted changes from baseline and
differences between combination and solifenacin 5 mg. The ﬁrst key
secondary end point, mean daily micturition frequency, was analysed
using an ANCOVA model with the same ﬁxed factors and baseline
micturitions as the covariate. The number of incontinence episodes noted
in the 3-d diary was analysed using a mixed-effects Poisson regression
model (negative binomial to accommodate for overdispersion [21]),
including treatment group, randomisation stratiﬁcation factors, and log of
numberof incontinenceepisodesduringbaseline, toderive therate ratioof
combination versus solifenacin 5 mg (Supplement 2, sect. ii and iii).
Noninferiority testing of combination versus solifenacin 10 mg for
change from baseline to EOT in mean daily micturitions was performed
in the same ANCOVA model with a noninferiority margin of 0.20
micturitions per 24 h; noninferiority was concluded if the upper limit of
the two-sided 95% conﬁdence interval (CI) for the mean treatment
differencewas<0.20, and superiority was concluded if the upper limit for
the treatment difference was <0. The number of incontinence episodes
noted in the 3-d diarywas analysed using the samemixed-effects Poisson
regression (negative binomial) model. The noninferiority margin was set
to 1.11; noninferiority was concluded if the upper limit of the two-sided
95%CI for the rate ratiowas<1.11; superioritywas concluded if the upper
limit of the two-sided 95% CI for the rate ratio was <1.
Other secondary efﬁcacy variables that were normally distributed
were analysed using the ANCOVA model described for micturition
frequency. Odds ratios, 95% CIs, and p values for responder rates for zero
incontinence episodes at EOT were derived from a logistic regression
model. Changes in vital signs were analysed using an ANCOVA model
[(Fig._2)TD$FIG]
Fig. 2 – Patient disposition.
AE = adverse event; eCRF = electronic case report form; EOT = end of treatment.
* Two patients in the combination group discontinued but had no EOT page in the eCRF; therefore, the reasons for discontinuation were not reported.
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iv and v).
3. Results
3.1. Patient demographics
Overall, 2174 patients were randomised to combination
(n = 727), solifenacin 5 mg (n = 728), or solifenacin 10 mg
(n = 719) (Fig. 2). Patient demographics and baseline
characteristics were similar across the treatment groups
(Table 1).
3.2. Efficacy
In the FAS, the adjusted change from baseline to EOT in the
mean number of incontinence episodes per 24 h (primary
end point) was statistically significantly greater with
combination (1.80) versus solifenacin 5 mg (1.53)
(Fig. 3a). At EOT, reductions in mean daily micturitions
and in 3-d incontinence episodes were statistically signifi-
cantly greater with combination versus solifenacin 5 mg
(Fig. 3b and 3c). Combination was noninferior to solifenacin
10 mg for both key secondary end points and superior to
solifenacin 10 mg for the reduction inmicturition frequency
using both the FAS (Fig. 3b and 3c) and PPS (Supplementary
Fig. 1). Significant differences in favour of the combination
were evident as early as week 4 versus solifenacin 5 mg and
week 8 versus solifenacin 10 mg (Fig. 3d[14_TD$DIFF]–f). Significantly
more patients became dry at EOT with combination (46.0%)versus solifenacin 5 mg (37.9%) and 10 mg (40.2%); the odds
ratios versus solifenacin 5 and 10 mg were 1.47 (95% CI,
1.17–1.84) and 1.28 (95% CI, 1.02–1.61), respectively
(Table 2).
Significant improvements in all secondary efficacy end
points (except nocturia) were demonstrated with combi-
nation versus solifenacin 5 mg and for most of the end
points versus solifenacin 10 mg (Table 2). Subgroup
analyses showed improvements in the primary and key
secondary end points with combination versus solifenacin
monotherapy that were independent of age (<65 or65 yr)
for incontinence and micturition frequency and indepen-
dent of sex for micturition frequency; improvements in
incontinence with combination versus solifenacin mono-
therapy were evident only in the larger female population
(Supplementary Table 2).
3.3. Tolerability
The incidence of TEAEs was lowest with solifenacin 5 mg
(33.1%), highest with solifenacin 10 mg (39.4%), and 35.9%
with combination; dry mouth and constipation were the
most common TEAEs. Incidence of dry mouth was lower
with combination (5.9%) versus solifenacin 10 mg (9.5%)
and similar to solifenacin 5 mg (5.6%) (Table 3). Other
differences in TEAEs included hypersensitivity reactions
(combination [1.5%], solifenacin 5 and 10 mg [0.8%]) and
constipation (combination [4.6%], solifenacin 5 mg [3.0%],
and 10 mg [4.7%]). There were no occurrences of acute
urinary retention requiring catheterisation.
Table 1 – Summary of demographics, baseline characteristics, and baseline characteristics related to overactive bladder (full analysis set)
Combination
n = 707
Solifenacin 5 mg
n = 705
Solifenacin 10 mg
n = 698
Sex, n (%)
Female 588 (83.2) 584 (82.8) 585 (83.8)
Male 119 (16.8) 121 (17.2) 113 (16.2)
Race, n (%)
White 671 (94.9) 656 (93.0) 661 (94.7)
Black/African American 19 (2.7) 24 (3.4) 26 (3.7)
Asian 13 (1.8) 21 (3.0) 9 (1.3)
Other 4 (0.6) 4 (0.6) 2 (0.3)
Age, yr, mean (SD) 58.0 (13.2) 56.9 (13.4) 57.3 (13.2)
65 yr, n (%) 223 (31.5) 214 (30.4) 214 (30.7)
75 yr, n (%) 71 (10.0) 64 (9.1) 53 (7.6)
BMI, kg/m2
Mean (SD) 29.0 (5.9) 29.1 (6.3) 29.0 (6.0)
Mean duration of OAB, mo 75.8 67.8 70.1
Previous OAB medication prior to screening, n (%) 474 (67.0) 487 (69.1) 479 (68.6)
Previous OAB medications, n (%)
0 233 (33.0) 218 (30.9) 219 (31.4)
1 266 (37.6) 268 (38.0) 259 (37.1)
2 114 (16.1) 129 (18.3) 116 (16.6)
>2 94 (13.3) 90 (12.8) 104 (14.9)
Previous OAB medication discontinued, n (%)
Insufﬁcient effect 423 (89.2) 428 (87.9) 417 (87.1)
Poor tolerability 89 (18.8) 96 (19.7) 106 (22.1)
Previous solifenacin treatment prior to screening, n (%) 269 (38.0) 297 (42.1) 281 (40.3)
Previous mirabegron treatment prior to screening, n (%) 43 (6.1) 39 (5.5) 41 (5.9)
No. of incontinence episodes during 3-d diary, mean (SD) 9.6 (8.9) 9.4 (8.1) 9.9 (9.1)
No. of incontinence episodes/24 h, mean (SD) 3.23 (3.00) 3.16 (2.73) 3.31 (3.05)
No. of micturitions/24 h, mean (SD) 9.12 (2.79) 8.90 (2.72) 8.96 (2.75)
Urgency incontinence episodes/24 h, mean (SD), n 2.94 (2.77), 692 2.86 (2.49), 684 3.01 (2.75), 667
Pads/24 h, mean (SD), n 2.74 (2.51), 511 2.79 (2.38), 477 2.92 (2.62), 487
Urgency episodes (grade 3 or 4)/24 h, mean (SD), n 5.83 (3.83), 700 5.69 (3.59), 695 5.79 (3.72), 681
Nocturia episodes/24 h, mean (SD), n 1.51 (1.06), 538 1.45 (0.96), 524 1.50 (1.03), 532
BMI = body mass index; OAB = overactive bladder; SD = standard deviation.
The full analysis set included all randomised patients who took at least one dose of the double-blind study drug after randomisation and reported at least one
micturition and at least one incontinence episode in the baseline diary and at least one micturition after baseline.
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between combination and solifenacin monotherapy at EOT
(Supplementary Fig. 2). There were no notable differences
in vital signs (Supplementary Fig. 2) including subpopula-
tions stratified by hypertensive status and b-blocker use
(Supplementary Table 3), and there were no notable
changes in ECG parameters or PVR volume (Supplementary
Table 4); very few patients (five or fewer per group) had
potentially clinically significant changes in haematology or
liver function parameters (Supplementary Table 5) across
the three treatment groups.
4. Discussion
Combining two oral pharmacotherapies with distinct
modes of action and proven efficacy may improve OAB
symptoms without exacerbating anticholinergic burden,
possibly obviating the need for dose escalation or more
invasive interventions.
In this significantly incontinent OAB population, who
were predominantly female and characterised by an
average of three or more episodes per 24 h, the once-daily
combination (solifenacin 5 mg andmirabegron 50 mg)was
associated with an improvement in key OAB symptoms
and was well tolerated compared with solifenacinmonotherapy. Combination therapy for 12wk significantly
reducedmeandaily incontinence episodes (0.26 episodes
per 24 h), 3-d incontinence episodes (18% reduction), and
daily micturition frequency (0.45 micturitions per 24 h)
versus solifenacin 5 mg. Themagnitude of improvement in
daily incontinence and micturition frequency compares
favourably with mirabegron 50 mg versus placebo (0.40
and 0.55) in [15_TD$DIFF]‘‘wet [16_TD$DIFF]’’ and [17_TD$DIFF]‘‘dry [18_TD$DIFF]’’ patients [22], suggesting an
additive treatment effect with combination. These
improvements with combination were associated with
clinically meaningful improvements in patient-reported
outcomes (PROs; data on file to be published). Combination
was noninferior to solifenacin 10 mg for both key second-
ary end points (micturition frequency and 3-d inconti-
nence) and superior to solifenacin 10 mg for micturition
frequency, and several other secondary efficacy end points.
The improvements observed with combination versus
solifenacin 10 mg were statistically significant for all
efficacy end points, with the exception of nocturia and
3-d incontinence.
Incontinent (‘‘wet’’) OAB patients experience greater
impairment in QoL and physical functioning than those
experiencing frequency and urgency without incontinence
[23,24]. Therefore promoting the transition from a ‘‘wet’’ to
a ‘‘dry’’ patient is expected to improve QoL significantly. In
Table 2 – Change from baseline to end of treatment and treatment difference versus solifenacin for the other secondary end points (full
analysis set)
Combination
(n = 707)
Solifenacin 5 mg
(n = 705)
Solifenacin 10 mg
(n = 698)
Mean volume voided/micturition n = 680 n = 682 n = 682
Adjusted change from baseline to EOT, mean (SE) 28.05 (1.97) 16.52 (1.97) 20.30 (1.97)
Differences of adjusted means: combination vs solifenacin 5 mg, mean (SE) (95% CI) 11.52 (2.79)
(6.06–16.99)
p < 0.001
Differences of adjusted means: combination vs solifenacin 10 mg, mean (SE) (95% CI) 7.75 (2.79)
(2.29–13.21)
p = 0.005
Urgency incontinence episodes/24 h n = 691 n = 683 n = 666
Adjusted change from baseline to EOT, mean (SE) –1.82 (0.07) –1.54 (0.07) –1.63 (0.07)
Differences of adjusted means: combination vs solifenacin 5 mg, mean (SE) (95% CI) –0.27 (0.10)
(–0.47 to –0.07)
p = 0.003
Differences of adjusted means: combination vs solifenacin 10 mg, mean (SE) (95% CI) –0.19 (0.10)
(–0.39 to 0.01)
p = 0.014
Urgency episodes (grade 3 and/or 4)/24 h n = 699 n = 694 n = 680
Adjusted change from baseline to EOT, mean (SE) –2.95 (0.10) –2.41 (0.10) –2.54 (0.11)
Differences of adjusted means: combination vs solifenacin 5 mg, mean (SE) (95% CI) –0.54 (0.15)
(–0.83 to –0.25)
p < 0.001
Differences of adjusted means: combination vs solifenacin 10 mg, mean (SE) (95% CI) –0.40 (0.15)
(–0.69 to –0.11)
p = 0.007
Mean number of pads/24 h n = 510 n = 476 n = 487
Adjusted change from baseline to EOT, mean (SE) –1.66 (0.07) –1.35 (0.07) –1.43 (0.07)
Differences of adjusted means: combination vs solifenacin 5 mg, mean (SE) (95% CI) –0.31 (0.10)
(–0.51 to –0.12)
p = 0.002
Differences of adjusted means: combination vs solifenacin 10 mg, mean (SE) (95% CI) –0.23 (0.10)
(–0.42 to –0.04)
p = 0.020
Mean number of nocturia episodes n = 537 n = 523 n = 531
Adjusted change from baseline to EOT, mean (SE) –0.43 (0.03) –0.37 (0.03) –0.41 (0.03)
Differences of adjusted means: combination vs solifenacin 5 mg, mean (SE) (95% CI) –0.06 (0.05)
(–0.16 to 0.03)
p = 0.174
Differences of adjusted means: combination vs solifenacin 10 mg, mean (SE) (95% CI) –0.02 (0.05)
(–0.11 to 0.07)
p = 0.634
Change from baseline in PPBC score n = 687 n = 685 n = 677
Adjusted change from baseline to EOT, mean (SE) –1.5 (0.0) –1.2 (0.0) –1.3 (0.0)
Differences of adjusted means: combination vs solifenacin 5 mg, mean (SE) (95% CI) –0.3 (0.1)
(–0.4 to –0.1)
p < 0.001
Differences of adjusted means: combination vs solifenacin 10 mg, mean (SE) (95% CI) –0.2 (0.1)
(–0.3 to –0.1)
p = 0.004
Responders for zero incontinence
Responders (%) at EOT 325/706 (46.0) 267/704 (37.9) 280/697 (40.2)
Difference (95% CI) vs solifenacin 5 mg 8.11 (2.97–13.24)
Odds ratio (95% CI) vs solifenacin 5 mg 1.47 (1.17–1.84)
p = 0.001
Difference (95% CI) vs solifenacin 10 mg 5.86 (0.69–11.04)
Odds ratio (95% CI) vs solifenacin 10 mg 1.28 (1.02–1.61)
p = 0.033
CI = conﬁdence interval; EOT = end of treatment; FAS = full analysis set; PPBC = Patient Perception of Bladder Condition; SE = standard error.
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ful given the higher percentage of continent patients at EOT
in the combination group; the odds of achieving zero
incontinence were 47% and 28% higher with combination
than solifenacin 5 or 10 mg, respectively. This compares
favourably with the 32% increased likelihood of being [19_TD$DIFF]‘‘dry[18_TD$DIFF]’’
reported with mirabegron 50 mg monotherapy versusplacebo in the mirabegron phase 3 studies, where inconti-
nence was less severe at baseline [22].
The absence of a significant improvement in nocturia
with combination versus solifenacin 5 mgwas probably due
to the multifactorial pathophysiology and often unclear
aetiology of nocturia in many patients [25]. Differences in
the onset of action of combination versus solifenacin 5 mg
[(Fig._3)TD$FIG]
Fig. 3 – Primary and key secondary end points (full analysis set) at end of treatment (EOT) [4_TD$DIFF]: (a) [5_TD$DIFF]change from baseline in the mean number of
incontinence episodes per 24 h; (b) change from baseline in the mean number of micturitions per 24 h; (c) number of incontinence episodes reported
in 3-d diary at EOT. Primary and key secondary end points at each study visit [6_TD$DIFF]: (d) mean number of incontinence episodes per 24 h; (e) mean number
of micturitions per 24 h; (f) number of incontinence episodes reported in 3[7_TD$DIFF]-d diary. (a, b, d, e) Adjusted change from baseline and 95% confidence
intervals for pairwise comparisons were derived from an analysis of covariance (ANCOVA) model with treatment group, sex, age group (<65 or I65 yr),
geographic region, and 4-[8_TD$DIFF]wk incontinence episode reduction group (<50%, I50%) as fixed factors and baseline value as covariate. A p < 0.05 indicates
superiority in favour of the treatment group with the largest improvement. (a, d [9_TD$DIFF]) The p values for pairwise comparisons are from a separate stratified
rank ANCOVA model. (b, e) The p values for pairwise comparisons are from an ANCOVA model. (c, f) Results are from a Poisson regression (negative
binomial) model including treatment group, sex, age group (<65 or I65 yr), geographic region, and 4-wk incontinence episode reduction group as
factors, log (number of incontinence episodes or number of valid diary days) at baseline as covariate and log (number of valid diary [10_TD$DIFF] days) as the offset
variable.
CI = confidence interval; EOT = end of treatment; SE = standard error.

[11_TD$DIFF] In the combination, the mirabegron dose was increased from 25 to 50 mg after week 4.
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been related to the different mirabegron doses before and
after week 4. In phase 3 mirabegron studies, the earliest
significant improvement in daily incontinence was ob-
served at week 4 with mirabegron 50 mg and week 8 with
mirabegron 25 mg compared with placebo [26].
Combination and solifenacin treatments were well
tolerated and generally comparable with the known safety
profiles of mirabegron and solifenacin. The overall inci-
dence of TEAEs with combination was lower than the 72.4%reported with mirabegron 50 mg add-on therapy to
solifenacin 5 mg in an open-label postmarketing Japanese
study [14]. The incidence of most TEAEs with the
combination was similar or lower than solifenacin 10 mg.
Dry mouth, the most frequently reported AE with anti-
muscarinics [27] and a common reason for treatment
discontinuation [7], was lower with combination versus
solifenacin 10 mg and similar to solifenacin 5 mg. The
relatively low rate of dry mouth with solifenacin 10 mgwas
probably a consequence of the initial 4-wk treatment with
Table 3 – Incidence and frequency of treatment-emergent adverse events (safety analysis set)
TEAE, n (%) Combination
(n = 725)
Solifenacin 5 mg
(n = 728)
Solifenacin 10 mg
(n = 719)
Any TEAE 260 (35.9) 241 (33.1) 283 (39.4)
Any drug-related* TEAE 141 (19.4) 125 (17.2) 161 (22.4)
Any serious TEAE 13 (1.8) 10 (1.4) 15 (2.1)
Any TEAE leading to withdrawal 11 (1.5) 11 (1.5) 11 (1.5)
Any TEAE leading to death 0 0 0
Common TEAEs** occurring in 1.5% of patients in any treatment group, n (%)
Dry mouth 43 (5.9) 41 (5.6) 68 (9.5)
Constipation 33 (4.6) 22 (3.0) 34 (4.7)
Oedema peripheral 6 (0.8) 16 (2.2) 2 (0.3)
Diarrhoea 12 (1.7) 5 (0.7) 6 (0.8)
Nasopharyngitis 14 (1.9) 13 (1.8) 14 (1.9)
Urinary tract infection 7 (1.0) 7 (1.0) 12 (1.7)
Headache 9 (1.2) 13 (1.8) 12 (1.7)
Dizziness 6 (0.8) 11 (1.5) 8 (1.1)
Somnolence 11 (1.5) 7 (1.0) 4 (0.6)
TEAEs of interest**
Increased blood pressure 12 (1.7) 6 (0.8) 13 (1.8)
QT prolongation 1 (0.1) 1 (0.1) 2 (0.3)
Increased heart rate, tachycardia, atrial ﬁbrillation, and palpitations 7 (1.0) 5 (0.7) 4 (0.6)
Tachycardia 2 (0.3) 3 (0.4) 1 (0.1)
Urinary tract infection 17 (2.3) 16 (2.2) 20 (2.8)
Urinary retentiony 2 (0.3) 1 (0.1) 5 (0.7)
Acute urinary retentiony 0 0 0
Hypersensitivity reactions 11 (1.5) 6 (0.8) 6 (0.8)
Glaucoma 0 0 0
SAF = safety analysis set; TEAE = treatment-emergent adverse event.
* Possible or probable, as assessed by the investigator, or records where the relationship was missing.
** Based on Standardised MedDRA Queries (SMQs) or sponsor-deﬁned lists of Preferred Terms if no SMQ was available.
y Urinary retention by preferred term, and acute urinary retention by lower level term. None of the cases of urinary retention required catheterisation in any
treatment group.
E U RO P E AN URO LOG Y 7 0 ( 2 0 1 6 ) 1 3 6 – 1 4 5 143solifenacin 5 mg, which may have encouraged the selection
of more tolerable or adaptable patients to antimuscarinic-
related AEs. Vital signs, ECG parameters, and PVR volume in
the combination group showed no synergistic effects
beyond those known from either monotherapy. The
difference in SBP (approximately 1 mm Hg) with combina-
tion versus solifenacin monotherapy was attributed to a
decrease in SBP with solifenacin monotherapy; the magni-
tude of the change in SBP with combination was similar to
that observed in the mirabegron phase 3 studies [22]. There
was no important heterogeneity in response according to
hypertensive status or b-blocker use. A slightly higher
incidence of hypersensitivity reactions with combination
could in part be attributed to two cases involving clarithro-
mycin and omeprazole use, both well-documented potential
allergens [28,29], and twocasesof allergic rhinitis. Remaining
differences could be attributed to the combined hypersensi-
tivity profiles of mirabegron and solifenacin [30,31]. Despite
the limited incremental efficacy associatedwith combination
versus solifenacin 10mg, the improved tolerability profile
compared with solifenacin 10mg and information gathered
through PRO tools (data on file) suggest that combining
mirabegron and solifenacin may be a clinically acceptable
alternative to dose escalation of solifenacin.
The option to include a mirabegron 50 mg monotherapy
arm was not undertaken in BESIDE because it was designed
to investigate potential benefits of add-on mirabegron
therapy and not switch therapy, where such an inclusion
would have been more appropriate. The inclusion of amirabegron monotherapy arm would also have had an
impact on the sample size and study duration. A 2-wk
washout period for solifenacin 5 mg would be required
before commencing treatmentwithmirabegron; this would
not be the case for the combination arm. In a phase 3B
noninferiority trial in OAB patients refractory to previous
antimuscarinic therapy, mirabegron 50 mg did not demon-
strate superiority versus solifenacin 5 mg [32]. The SYNER-
GY [NCT01972841] and SYNERGY II [NCT02045862] trials,
which include mirabegron 25 and 50 mg arms, will provide
additional 12-wk and 52-wk data on the efficacy and safety
of the solifenacin/mirabegron combination.
5. Conclusions
Add-on therapywithmirabegron 50 mg for 12wkprovided
greater improvements in OAB symptoms in incontinent
OAB patients with an insufficient response to solifenacin
5 mg compared with solifenacin 5 or 10 mg monotherapy,
and it was well tolerated. The combination of solifenacin
andmirabegronneeds to be evaluated in clinical practice as
a potential alternative to the current approaches that
include dose escalation with conventional antimuscarinic
therapy or progression to more invasive third-line
therapies such as intravesical botulinum toxin [3_TD$DIFF]or neuro-
modulation.
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